The EIF4EBP1 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of human 143B osteosarcoma cells. This heterogeneous pool provides a loss-of-function model for studying EIF4EBP1-dependent translational control and mTOR signaling. The polyclonal format preserves genetic diversity while ensuring effective target-gene disruption, enabling pooled phenotypic analysis and minimizing clonal selection artifacts common in single-cell-derived knockouts. This model facilitates robust investigation of mTOR pathway biology in a cancer context.
The 143B line was established from a tumorigenic and metastatic osteosarcoma of a 13-year-old female. These osteoblast progenitor-derived malignant cells display aggressive growth in culture and in vivo, making them a rigorous model for osteosarcoma research. Their high metastatic capacity and tumorigenicity offer a relevant system for investigating pathways that drive tumor progression, including the mTOR axis. The line is widely employed in in vivo metastasis assays.
EIF4EBP1 (4E-BP1) is a translational repressor that binds eIF4E, preventing assembly of the eIF4F complex and inhibiting cap-dependent translation. Its activity is governed by mTORC1-mediated phosphorylation; hypophosphorylated 4E-BP1 sequesters eIF4E, whereas hyperphosphorylation triggers dissociation and permits translation. Upstream signals from IRS1, PI3K, AKT, and mTORC1 integrate growth factor and nutrient cues to modulate this switch. Downstream, the release of eIF4E promotes synthesis of oncoproteins like Cyclin D1 and MYC. Interacting factors including Raptor and PRAS40 further refine the mTORC1-4E-BP1 regulatory circuit.
In the 143B background, EIF4EBP1 knockout is expected to deregulate cap-dependent translation, leading to unrestrained eIF4E activity and enhanced production of pro-proliferative and anti-apoptotic proteins even under nutrient-limiting conditions. This may foster cell growth, survival, and metastatic behavior, mirroring mTOR pathway hyperactivation seen in cancer. The model thus allows dissection of 4E-BP1??s role in osteosarcoma pathogenesis, particularly in translational reprogramming and resistance to mTOR-targeted agents. It also facilitates examination of cross-talk with other signaling cascades such as PI3K-Akt.
These cells are suited for mTOR inhibitor studies (e.g., rapamycin treatment), polysome profiling, and co-immunoprecipitation of eIF4E complexes to assess translation regulation, with phospho-4E-BP1 Western blotting as a knockout validation control. Functional assays for proliferation, apoptosis, and migration/invasion can reveal phenotypic effects of 4E-BP1 loss. The model also supports drug resistance screens and crosstalk analysis between mTOR and other oncogenic pathways. For additional technical information or customization, contact Ascent Research.
